Status:
COMPLETED
The Triglyceride Lowering Effect of an Omega-3 Fat (DHA) in Addition to Statin Therapy for Patients With CAD or Diabetes
Lead Sponsor:
Maine Center for Lipids and Cardiovascular Health
Conditions:
Hypertriglyceridemia (TG>200<500)
Hyperlipidemia
Eligibility:
All Genders
21-80 years
Phase:
NA
Brief Summary
This study will explore the ability of an algae (ocean plant) omega-3 fat supplement (DHA) to reduce triglyceride levels in patients currently being treated with statin therapy (Zocor or simvastatin, ...
Detailed Description
Omega-3 fatty acids (nPUFAs) have been embraced by Expert Panels and Guideline Committees of the American Heart Association as a result of randomized trials documenting reductions in cardiovascular ev...
Eligibility Criteria
Inclusion
- CAD or Risk Equivalent
- On any statin therapy
- At NCEP LDL goal (\<100)
- TG\>200 mg%
Exclusion
- TG\>500, TG levels that vary more than 25% during base-line
- Poorly controlled DM
- BMI\>40
- Use of fibrates, niacin, other fish oil product
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00360217
Start Date
January 1 2006
End Date
May 1 2007
Last Update
November 18 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maine Center for Lipids and Cardiovascular Health
Scarborough, Maine, United States, 04074